The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era

다국어 초록 (Multilingual Abstract)

Purpose We aim to examine nasopharyngeal carcinoma (NPC) characteristics and survival outcomes in patients aged 70 years and older in the intensity-modulated radiotherapy (IMRT) era.
Materials and Methods From 2006 to 2013, 126 non-metastatic NPC patients aged  70 years who were treated with IMRT +/ chemotherapy were included. Adult Comorbidity Evaluation 27 (ACE-27) was used to measure patient comorbidities. The overall survival (OS) and cancer-specific survival (CSS) were calculated with the Kaplan-Meier method, and differences were compared using the log-rank test. The Cox proportional hazards model was used to carry out multivariate analyses.
Results For the entire group, only two patients (1.6%) presented stage I disease, and up to 84.1% patients had stage III-IVB disease. All patients had a comorbidity score of 0 in 24 (19.0%), 1 in 45 (35.7%), 2 in 42 (33.3%), and 3 in 15 (11.9%) patients. The main acute grade during radiotherapy was 3-4 adverse events consisting of mucositis (25.4%), bone marrow suppression (16.7%), and dermatitis (8.7%). After treatment, four patients (3.2%) developed temporal lobe injury. Five-year CSS and OS rates were 67.3% (95% confidence interval [CI], 58.6% to 77.4%) and 54.0% (95% CI, 45.6% to 63.9%), respectively. Five-year OS was significantly higher for ACE-27 score 0-1 than ACE-27 score 2-3 (72.9% and 39.9%, respectively; p < 0.001). Multivariate analyses showed ACE-27 score 0-1 was significantly associated with superior OS (hazard ratio [HR], 3.02; 95% CI, 1.64 to 5.55; p < 0.001). In addition, the rate of OS was higher for stage I-III than that of stage IV, with borderline significance (HR, 1.67; 95% CI, 0.99 to 2.82; p=0.053). But no significant advantage was observed in OS when chemotherapy was used (p > 0.05).
Conclusion Our findings suggest IMRT +/– chemotherapy has a manageable toxicity and provides an acceptable survival in patients aged  70 years with NPC. ACE-27 score was significantly associated with survival outcomes in this group population.

참고문헌 (Reference)

1 United Nations, "World population prospects: the 2010 revision" United Nations 2011

2 Tang LQ, "The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis : an observational study" 111 : 1102-1111, 2014

3 Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM" 17 : 1471-1474, 2010

4 Hui EP, "Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma" 27 : 242-249, 2009

5 Sze HC, "Radical radiotherapy for nasopharyngeal carcinoma in elderly patients : the importance of co-morbidity assessment" 48 : 162-167, 2012

6 Zhou GQ, "Radiation-induced temporal lobe injury for nasopharyngeal carcinoma:a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy" 8 : e67488-, 2013

7 Piccirillo JF, "Prognostic importance of comorbidity in a hospital-based cancer registry" 291 : 2441-2447, 2004

8 ICRU, "Prescribing, recording, and reporting photonbeam intensity-modulated radiation therapy (IMRT)" International Commission on Radiation Units and Measurements 2010

9 ICRU, "Prescribing, recording, and reporting photon beam therapy" International Commission on Radiation Units and Measurements 1999

10 Yi JL, "Nasopharyngeal carcinoma treated by radical radiotherapy alone : ten-year experience of a single institution" 65 : 161-168, 2006

11 Lee AW, "Nasopharyngeal carcinoma : presenting symptoms and duration before diagnosis" 3 : 355-361, 1997

12 Chua ML, "Nasopharyngeal carcinoma" 387 : 1012-1024, 2016

13 Lin JC, "Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy" 68 : 1342-1348, 2007

14 Li WF, "Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation" 31 : 579-587, 2012

15 Zeng L, "Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma : patient and treatment-related risk factors" 110 : 49-54, 2014

16 Kong C, "LASSO-based NTCP model for radiation-induced temporal lobe injury developing after intensity-modulated radiotherapy of nasopharyngeal carcinoma" 6 : 26378-, 2016

17 Guo R, "Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma?" 104 : 294-299, 2012

18 Zhang MX, "Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up" 51 : 2587-2595, 2015

19 Zhang Y, "Inherently poor survival of elderly patients with nasopharyngeal carcinoma" 37 : 771-776, 2015

20 Xiao G, "Influence of gender and age on the survival of patients with nasopharyngeal carcinoma" 13 : 226-, 2013

21 Zhang LF, "Incidence trend of nasopharyngeal carcinoma from 1987 to 2011in Sihui County, Guangdong Province, South China : an ageperiod-cohort analysis" 34 : 350-357, 2015

22 Piccirillo JF, "Importance of comorbidity in head and neck cancer" 110 : 593-602, 2000

23 Cheung MC, "Impact of radionecrosis on cognitive dysfunction in patients after radiotherapy for nasopharyngeal carcinoma" 97 : 2019-2026, 2003

24 Paleri V, "Impact of comorbidity on the outcome of laryngeal squamous cancer" 25 : 1019-1026, 2003

25 Lai SZ, "How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?" 80 : 661-668, 2011

26 Rogers SN, "Feasibility study of the retrospective use of the Adult Comorbidity Evaluation index(ACE-27)in patients with cancer of the head and neck who had radiotherapy" 44 : 283-288, 2006

27 Liu H, "Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma : results from a matched cohort analysis" 8 : 70-, 2013

28 Wang YX, "Evolution of radiation-induced brain injury : MR imagingbased study" 254 : 210-218, 2010

29 Chen L, "Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma : a phase 3 multicentre randomised controlled trial" 13 : 163-171, 2012

30 Ramakrishnan Y, "Comorbidity in nasopharyngeal carcinoma : a preliminary communication on the prevalence, descriptive distribution and impact on outcome" 32 : 484-488, 2007

31 Bortolin MT, "Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type" 233 : 247-254, 2006

32 Peng G, "A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma" 104 : 286-293, 2012

33 Zeng Q, "A matched cohort study of standard chemo-radiotherapy versus radiotherapy alone in elderly nasopharyngeal carcinoma patients" 10 : e0119593-, 2015